Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

Micro-Abstract The incidence of acute myeloid leukemia (AML) increases with age, with poor prognosis in older patients. We report findings from a dose-escalation study of barasertib, an Aurora B kinase inhibitor, plus low-dose cytosine arabinoside (LDAC) in 22 AML patients aged 60 years or older. Th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2013-10, Vol.13 (5), p.559-567
Hauptverfasser:	Kantarjian, Hagop M, Sekeres, Mikkael A, Ribrag, Vincent, Rousselot, Philippe, Garcia-Manero, Guillermo, Jabbour, Elias J, Owen, Kate, Stockman, Paul K, Oliver, Stuart D
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Age Factors Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Barasertib-hQPA Cytarabine - administration & dosage Cytarabine - pharmacokinetics Dose-escalation study Female Hematology, Oncology and Palliative Medicine Humans Leukemia, Myeloid, Acute - drug therapy Male Middle Aged Organophosphates - administration & dosage Organophosphates - pharmacokinetics Quinazolines - administration & dosage Quinazolines - pharmacokinetics Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract The incidence of acute myeloid leukemia (AML) increases with age, with poor prognosis in older patients. We report findings from a dose-escalation study of barasertib, an Aurora B kinase inhibitor, plus low-dose cytosine arabinoside (LDAC) in 22 AML patients aged 60 years or older. The maximum tolerated dose (MTD) of barasertib was 1000 mg. A preliminary overall response rate of 45% was reported.
ISSN:	2152-2650 2152-2669
DOI:	10.1016/j.clml.2013.03.019